TCRX advances solid-tumor TCR programs to IND-enabling stage
TCRX said two in vivo solid-tumor TCR therapies (PRAME, MAGE-A4) moved to IND-enabling stage with clinical trials planned for late 2027. Heme and autoimmune efforts are paused; financial runway extended into Q4 2027.
Two in vivo TCR therapies for solid tumors (PRAME, MAGE-A4) advanced to IND-enabling stage, with clinical trials planned for late 2027.
Heme malignancy program paused after strong early results, pending partnerships, and autoimmune efforts halted for now.
Financial runway extended into Q4 2027.Base…